New drug combo tested for Hard-to-Treat cancers

NCT ID NCT04446351

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new experimental drug called GSK6097608, given alone or with other cancer medicines, in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 107 adults with various advanced cancers are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site

Los Angeles, California, 90025, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Dallas, Texas, 75230, United States
GSK Investigational Site

Houston, Texas, 77030-4009, United States
GSK Investigational Site

San Antonio, Texas, 78229, United States
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 1Z5, Canada
GSK Investigational Site

Chiba, 277-8577, Japan
GSK Investigational Site

Tokyo, 104-0045, Japan
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.